Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00593008 · ClinicalTrials.gov registry record · Phase 1
Temsirolimus in Combination With Gemcitabine in Previously Untreated Metastatic Pancreatic Cancer
A Phase 1 study, sponsored by Massachusetts General Hospital.
- Terminated
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT00593008: Clinical Trial Phase 1 study, sponsored by Massachusetts General Hospital.
NCT00593008 is a Phase 1 study that was terminated before completion, run by Massachusetts General Hospital. The registered enrollment target is 5 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00593008, a Phase 1 study, was terminated before completion, sponsored by Massachusetts General Hospital.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
The purpose of this research study is to try to define the highest doses of temsirolimus and gemcitabine that can be used safely in combination to treat advanced pancreatic cancer. Gemcitabine is a standard chemotherapy used for the treatment of pancreatic cancer.
Interventions
- DRUG Gemcitabine
- DRUG Temsirolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2007-10 |
| Est. Completion | 2009-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00593008
The ClinicalTrials.gov registry entry for NCT00593008 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Gemcitabine is the first listed.
NCT00593008 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00593008 about?
NCT00593008 is a clinical study titled "Temsirolimus in Combination With Gemcitabine in Previously Untreated Metastatic Pancreatic Cancer". The purpose of this research study is to try to define the highest doses of temsirolimus and gemcitabine that can be used safely in combination to treat advanced pancreatic cancer. Gemcitabine is a standard chemotherapy used for the treatment of pancreatic cancer.
What is the current status of trial NCT00593008?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2007-10. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00593008?
The interventions under investigation include: Gemcitabine (DRUG), Temsirolimus (DRUG).
Who is sponsoring clinical trial NCT00593008?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.